Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026

Medtronic reports strong real-world safety and efficacy data for its cardiac ablation systems.

What the company is saying

Medtronic plc (NYSE:MDT) is highlighting positive real-world registry results for its Affera Mapping and Ablation System with the Sphere-9 Catheter and the PulseSelect Pulsed Field Ablation (PFA) System. The company frames these outcomes as evidence of both safety and procedural success across atrial and ventricular arrhythmias, using phrases like 'reinforce our confidence' and 'positive impact' to emphasize the strength of the data. Khaldoun Tarakji, Vice President and Chief of Science, Research and Technology for Electrophysiology Therapies, and Felicia Kurz, Vice President and General Manager of Cardiac Ablation Solutions, are both quoted to lend institutional credibility and underscore Medtronic’s leadership in cardiac ablation. The announcement spotlights low complication rates, high acute success, and the breadth of global patient enrollment. Medtronic also notes the regulatory status of its products, stating that Sphere-9 is CE marked for VT but not approved for VT in the United States, and that regulatory clearance may not be universal. The tone is confident and forward-looking, with an emphasis on continued innovation and leadership in the field.

What the data suggests

The APEX registry included 1,050 atrial fibrillation patients treated with the Sphere-9 catheter and Affera Mapping and Ablation System across 28 global sites, reporting a major complication rate of 1.1% and no cases of acute kidney injury, severe coronary spasm, or phrenic nerve injury. There was no significant difference in complication rates between de novo and repeat ablation procedures, though no statistical details are disclosed. The REAL PULSE registry enrolled 1,160 atrial fibrillation patients at 38 global sites using the PulseSelect PFA system, achieving a 100% acute success rate and a low acute major complication rate of 0.09%. In a separate European APEX registry for ventricular tachycardia, 46 patients were treated with the Sphere-9 catheter, with high acute success (87%) and an estimated six-month freedom from VT recurrence of 75%; six major complications occurred in four patients. No significant difference in long-term arrhythmia recurrence was observed between ischemic and non-ischemic cardiomyopathy patients, but no detailed statistics are provided. The data is robust in terms of patient numbers and geographic diversity, but lacks financial metrics and detailed statistical analysis for some qualitative claims.

Analysis

The announcement presents detailed, realised clinical registry results for Medtronic's ablation technologies, with specific patient numbers, complication rates, and acute success rates. Most claims are supported by disclosed numerical data, and the results are framed as positive, reinforcing the safety and efficacy of the products. However, the tone is somewhat inflated by qualitative statements such as 'reinforce confidence' and 'positive impact,' which are not directly quantified. Some claims (e.g., 'no significant difference') lack supporting statistical evidence. Importantly, there is no disclosure of financial metrics (revenue, profit, margins), so the true_signal cannot exceed weak_positive per the Disclosure Completeness Rule. The forward-looking content is limited to regulatory status and general innovation statements, with the majority of claims being realised clinical outcomes.

Risk flags

• ●Regulatory risk remains for the Sphere-9 catheter in ventricular tachycardia, as it is only CE marked and not approved for VT in the United States; approval timelines and outcomes are uncertain and could limit market access.
• ●The absence of detailed statistical analysis for claims of 'no significant difference' between patient subgroups limits the ability to fully verify the robustness of subgroup outcomes, introducing a risk of overinterpretation.
• ●While complication rates are low, six major complications in four VT patients out of 46 treated highlight that procedural risks persist, and broader real-world use could reveal additional safety concerns.
• ●No financial data or commercial uptake figures are disclosed, so the impact of these clinical results on revenue or market share cannot be directly assessed, leaving a gap in understanding the business implications.

Bottom line

Medtronic's registry data demonstrates strong safety and efficacy for its cardiac ablation technologies, with low complication rates (1.1% for Sphere-9 in AFib, 0.09% for PulseSelect PFA) and high acute success (100% for PulseSelect, 87% for Sphere-9 in VT). These results support the company's narrative of technological leadership and may help drive adoption, but the lack of financial disclosure means investors cannot gauge the immediate commercial impact. Regulatory uncertainty for the VT indication in the U.S. remains a key hurdle. The most important takeaway is that Medtronic’s ablation portfolio is clinically validated in large, diverse patient populations, but the translation to revenue growth and market expansion will depend on future regulatory and commercial developments. Investors should watch for updates on U.S. approvals and any future disclosures linking these clinical outcomes to sales performance.

Announcement summary

(NYSE:MDT) Medtronic plc announced positive real-world registry results for its Affera Mapping and Ablation System with the Sphere-9 Catheter and the PulseSelect Pulsed Field Ablation (PFA) System. The APEX global prospective registry analysis included 1,050 patients with atrial fibrillation (AFib) treated with the Sphere-9 catheter and Affera Mapping and Ablation System across 28 global sites. The major complication rate in this cohort was 1.1%, with no acute kidney injury, severe coronary spasm, or phrenic nerve injury reported. Major complication rates did not differ significantly between de novo and repeat ablation procedures. The REAL PULSE global prospective registry analysis included 1,160 AFib patients treated with the PulseSelect PFA system across 38 global sites. This analysis showed a 100% acute success rate and a low acute major complication rate of 0.09%. A separate European APEX registry analysis evaluated the Sphere-9 catheter in 46 patients with ischemic and non-ischemic sustained ventricular tachycardia (VT), demonstrating high acute success at 87% and an estimated six-month freedom from VT recurrence at 75%. Six major complications were reported in four patients in the VT cohort. There was no significant difference in long-term freedom from arrhythmia recurrence between ischemic and non-ischemic cardiomyopathy patients. The Sphere-9 catheter is CE marked for VT but is investigational only and not approved for VT in the United States, and the ventricular ablation indication may not be approved or cleared in all markets. Khaldoun Tarakji, M.D., MPH, Vice President and Chief of Science, Research and Technology, Electrophysiology Therapies at Medtronic, stated that these results reinforce confidence in the safety and performance of Medtronic's ablation technologies. Felicia Kurz, Vice President and General Manager, Cardiac Ablation Solutions, Electrophysiology Therapies at Medtronic, commented on the positive impact of long-term data supporting the safety and efficacy profiles of the company's ablation technologies. The Medtronic cardiac ablation portfolio includes the Sphere-9 catheter, which combines high-definition mapping with pulsed field and radiofrequency ablation, and the PulseSelect PFA system, a single-shot solution for pulmonary vein isolation. Medtronic employs 95,000 people across 150 countries.

Disagree with this article?